ARS Pharmaceuticals Q1 revenue hits $22.7M as Neffy sales scale
ARS Pharmaceuticals (NASDAQ:SPRY) reported its first-quarter 2026 financial results, highlighted by accelerating domestic sales for its needle-free allergy treatment alongside a broadening international regulatory footprint.





_1400751_640x360_2500183107863-640x360.webp&w=3840&q=75)
_1400738_640x360_2500185667645-640x360.webp&w=3840&q=75)


_1400728_640x360_2500184643983-640x360.webp&w=3840&q=75)

